Evidence Hub

Recognizing cutaneous signs of addiction: the “shooter's patch” and surrounding buckshot tattoos

R. Mital, C. Chung, B. Kaffenberger

International Journal of Dermatology, 2022

1 citation

Abstract

References 1 Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2020;8:83–5. https://doi.org/10.1016/j.jdcr.2020.12.010 2 Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76. https://doi. org/10.1016/j.jaad.2017.12.068 3 Mercer LK, Galloway JB, Lunt M, Davies R, Low ALS, Dixon WG, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2016;76:497–503. https://doi.org/10.1136/ annrheumdis-2016-209389 4 Dequidt L, Franck N, Sanchez-Pena P, Dalle S, Adamski H, Boulinguez S, et al. Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. Br J Dermatol. 2019;181(3):616–8. https://doi.org/10. 1111/bjd.17834 5 Napolitano M, Di Guida A, Nocerino M, et al. The emerging role of dupilumab in dermatological indications. Expert Opin Biol Ther. 2021;1–11. https://doi.org/10.1080/14712598.2021 6 Sugaya M. Is blocking IL-4 receptor alpha beneficial for patients with mycosis fungoides or S ezary syndrome? J Dermatol. 2021;48(5):e225–6. https://doi.org/10.1111/1346-8138.15834 7 Kołkowski K, Trzeciak M,…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free